GAITHERSBURG, Md.– GeneDx (Nasdaq: WGS) has completed its acquisition of Fabric Genomics, marking a significant step toward advancing the global integration of genomic insights into everyday clinical care. The deal combines GeneDx’s extensive rare disease testing expertise with Fabric’s AI-powered genomic interpretation platform to create a scalable, hybrid model for centralized and decentralized genomic services.
With the acquisition finalized, GeneDx aims to lead a new era of genomic medicine by delivering clinically actionable insights more efficiently and on a broader scale. The partnership enables the deployment of genomic testing directly within health systems while leveraging centralized intelligence to enhance diagnostic speed and accuracy.
“This marks a turning point for healthcare,” said Katherine Stueland, President and CEO of GeneDx. “With Fabric Genomics now part of GeneDx, we’re in a unique position to bring earlier and more accurate diagnoses to patients—whether in a NICU, a national newborn screening program, or a global health system.”
The integration of Fabric Genomics will enhance GeneDx’s ability to support critical initiatives such as genomic testing in neonatal intensive care units (NICUs), large-scale genomic newborn screening (gNBS), and international expansion of AI-powered interpretation services. Fabric will continue operating as a subsidiary of GeneDx, maintaining commercial momentum while gaining access to expanded resources and market reach.
The acquisition also introduces a recurring software-based revenue model for GeneDx through Fabric’s interpretation-as-a-service platform, contributing to stronger platform economics and sustainable growth.
Legal advisory for GeneDx was provided by Fenwick & West LLP. Fabric Genomics was advised by TD Cowen as financial advisor and DLA Piper LLP (US) as legal counsel.
